Regeren

Regeneron is a leading global biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. The company is renowned for its proprietary VelociSuite technology platform, which includes VelocImmune, enabling the rapid generation of fully human monoclonal antibodies. Its commercial portfolio is anchored by blockbuster therapies such as Eylea for retinal diseases and Dupixent for various inflammatory conditions, the latter co-developed with Sanofi. Regeneron maintains a robust clinical pipeline across oncology, ophthalmology, immunology, and rare diseases, utilizing its genetics research center to drive precision medicine initiatives.